Outlook Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. The company is headquartered in Cranbury, New Jersey.
| Revenue (TTM) | $-1.16M |
| Gross Profit (TTM) | $-2.28M |
| EBITDA | $-55.53M |
| Operating Margin | -124255.00% |
| Return on Equity | -3.65% |
| Return on Assets | -143.20% |
| Revenue/Share (TTM) | $-0.01 |
| Book Value | $-0.06 |
| Price-to-Book | 38.42 |
| Price-to-Sales (TTM) | 502.70 |
| EV/Revenue | 482.88 |
| EV/EBITDA | -4.13 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -99.40% |
| Shares Outstanding | $243.45M |
| Float | $176.57M |
| % Insiders | 12.64% |
| % Institutions | 25.44% |
Volatility is currently expanding
Veteran retina commercial leader, who has helped launch BEOVU®, EYLEA® and EYLEA® HD, to lead U.S. commercialization of LYTENAVA™ (bevacizumab-vikg) Veteran retina commercial leader, who has helped launch BEOVU®, EYLEA® and EYLEA® HD, to lead U.S. commercialization of LYTENAVA™ (bevacizumab-vikg)
Segment features Kevin Lundquist discussing his decision to join Outlook Therapeutics and the Company's path forward following the FDA approval of LYTENAVA™
Application represents an important step in supporting reimbursement Company remains on track for U.S. commercial launch of LYTENAVA before year-end 2026 ISELIN, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that it has submitted an application to the Centers for Medicare & Medicaid Services (CMS) requesting a permanent, product-specific Healthcare Common Procedure Coding System (HCPCS) Level II J-code for LYTENAVA.
PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Ionis Pharmaceuticals, Inc. today announced positive topline results from the Phase 3 FUSION trial evaluating ulefnersen, an investigational RNA-targeted medicine, in people living with a genetic subtype of amyotrophic lateral sclerosis (ALS) known as FUS-ALS, caused by mutations in the fused in sarcoma (FUS) gene1. The study met its primary end.
Fireside chat featuring Bob Jahr, Chief Executive Officer, and H.C. Wainwright Managing Director & Senior Biotechnology Equity Research Analyst
Access the segment here
Seasoned finance executive brings more than 20 years of leadership experience across global commercial organizations, including the pharmaceutical and medical technology industries Deep expertise spans commercial operations, capital markets, public company finance, and building scalable financial and operational infrastructure
Video webcast now available here
Outlook Therapeutics targets a year-end 2026 U.S. LYTENAVA launch, with $50M-$75M in first-year net revenues and a ramp tied to reimbursement.
Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on OTLK and any ticker you trade — then tracks every position and per-strategy win rate.
